| |
|
|
|
|
|
|
|||
|
Blood, 15 March 2007, Vol. 109, No. 6, pp. 2607-2610. Prepublished online as a Blood First Edition Paper on November 9, 2006; DOI 10.1182/blood-2006-04-019612.
Submitted April 27, 2006
Children's Cancer Research Institute, Austria * Corresponding author; email: renate.panzer{at}ccri.at.
The TEL/AML1 fusion gene results from the most frequent t(12;21)(p13;q22) translocation in childhood ALL. Its contribution to transformation is largely unknown, in particular with respect to survival and apoptosis. We therefore silenced TEL/AML1 expression in leukemic REH cells by RNA inhibition, which eventually led to programmed cell death. Microarray and 2D-gel electrophoresis data demonstrated a differential regulation of heat-shock proteins (HSPs), among them HSP90, as well as of its client, survivin. Consistent with these findings, ectopic expression of TEL/AML1 in Ba/F3 cells increased protein levels of HSP90 and survivin and conferred resistance to apoptotic stimuli. Our data suggest that TEL/AML1 does not only contribute to leukemogenesis by affecting an anti-apoptotic network but also seems to be indispensable for maintaining the malignant phenotype. The functional relationship between TEL/AML1, HSP90 and survivin provides the rational for targeted therapy, be it the fusion gene or the latter two proteins.
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Copyright © 2006 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||